Generation Bio

Performance

About Generation Bio

Generation Bio is a biotechnology company focused on selective delivery of siRNA to T cells using cell-targeted lipid nanoparticles (ctLNPs) to modulate T cell function and address T cell–driven autoimmune diseases. Their science emphasizes targeted gene silencing within T cells while sparing the broader immune system and avoiding uptake by liver and spleen. The company highlights its ctLNP-siRNA platform as a way to access new T cell targets and develop more potent, better-tolerated therapeutics. Headquartered in the United States, Generation Bio positions itself at the frontier of precision nucleic acid therapeutics for autoimmune conditions.